John Fetse

Assistant Professor, Department of Pharmaceutical Sciences
B.Pharm., M.Phil., Ph.D.
Office: 2303
Phone: 305-760-7471
Email: JFetse@larkin.edu
Hours: By Appointment

Education and Training

  • B.Pharm., Kwame Nkrumah University of Science and Technology,Kumasi, Ghana
  • M.Phil., Kwame Nkrumah University of Science and Technology, Kumasi, Ghana
  • Ph.D. University of Missouri-Kansas City, Kansas City, MO

 

Teaching Interests

Dr. Fetse’s teaching interests and experience include Pharmaceutics, Pharmacokinetics, Medicinal Chemistry and Pharmacology.

 

Scholarly Interests

Dr. John Fetse is an assistant professor of Pharmaceutical Sciences at Larkin University College of Pharmacy. Dr. Fetse’s research interest includes the discovery and delivery of peptide-based immune checkpoint inhibitors for cancer immunotherapy. His works focusses on the design, synthesis, and biological evaluation of cyclic peptides and peptidomimetics to target protein-protein interactions that mediate various immune checkpoint pathways. He is particularly interested in developing peptide-based immune checkpoint inhibitors that block the interaction between programmed cell death ligand-1 (PD-L1) and its receptor programmed cell death protein 1 (PD-1) for cancer immunotherapy. He is also working on the design of nanoformulations for delivering therapeutic payloads like small molecules, nucleic acids, peptides, and proteins.

 

Selected Recent Publications

  • John Fetse, Zhen Zhao, Hao Liu, Umar-Farouk Mamani, Bahaa Mustafa, Pratik Adhikary, Nurudeen Mohammed Ibrahim, Yanli Liu, Pratikkumar Patel, Maryam Nakhjiri, Mohammed Alahmari, Guangfu Li, Kun Cheng (2022). Discovery of Cyclic Peptide Inhibitors Targeting PD-L1 for Cancer Immunotherapy. ACS Journal of Medicinal Chemistry. doi.org/10.1021/acs.jmedchem.2c00539
  • Pratikkumar Patel, John Fetse, Chien-Yu Lin, Zhen Zhao, Maryam Nakhjiri, Akshay Jain, and Kun Cheng (2022). Development of Amino Acid-Modified Biodegradable Lipid Nanoparticles for siRNA Delivery. Acta Biomaterialia. doi.org/10.1016/j.actbio.2022.09.065
  • Pratik Adhikary, Sashi Kandel, Umar‐Farouk Mamani, Bahaa Mustafa, Siyuan Hao, Jianming Qiu, John Fetse, Yanli Liu, Nurudeen Mohammed Ibrahim, Yongren Li, Chien‐Yu Lin, Evanthia Omoscharka, Kun Cheng (2021) Discovery of Small Anti‐ACE2 Peptides to Inhibit SARS‐CoV‐2 Infectivity. Advanced Therapeutics. org/10.1002/adtp.202100087
  • Hao Liu, Zhen Zhao, Li Zhang, Yuanke Li, Akshay Jain, Ashutosh Barve, Wei Jin, Yanli Liu, John Fetse, Kun Cheng. (2019) Discovery of Low-Molecular Weight Anti-PD-L1 Peptides for Cancer Immunotherapy. Journal for Immunotherapy of Cancer. org/10.1186/s40425-019-0705-y
  • Akshay Jain, Ashutosh Barve, Zhen Zhao, John Peter Fetse, Hao Liu, Kun Cheng. (2019) Targeted Delivery of an siRNA-PNA Hybrid Nanocomplex Reverses Carbon Tetrachloride-Induced Liver Fibrosis. Advanced Therapeutics. doi.org/10.1002/adtp.201900046
  • Li, Yuanke, Zhen Zhao, Hao Liu, John Peter Fetse, Akshay Jain, Chien-Yu Lin, and Kun Cheng. (2019) “Development of a tumor-responsive nanopolyplex targeting pancreatic cancer cells and stroma.” ACS applied materials & interfaces. doi.org/10.1021/acsami.9b15116

Patents

  • Polypeptides and Compositions Comprising the Same (Inventors: Kun Cheng, Hao Liu, John Fetse, Umar-Farouk Mamani) US Patent App. 17/507,301, 2022
  • Polypeptides and Compositions Comprising the Same (Inventors: Kun Cheng, John Fetse, Hao Liu, Umar-Farouk Mamani), 63/104,256 (filed on 10/22/2020)